Etoposide-Induced Neutropenia

Introduction to Etoposide-Induced Neutropenia

The National Comprehensive Cancer Network recommends considering primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) for patients with risk factors for febrile neutropenia when using etoposide in combination with other myelosuppressive agents 1

Combination therapy with etoposide and other myelosuppressive agents increases the risk of neutropenia, as seen in regimens like BEP for testicular cancer or etoposide/platinum for small cell lung cancer, with a reported risk of grade 3/4 neutropenia as high as 85.2% 2
The use of etoposide in high-dose conditioning regimens for stem cell transplantation contributes significantly to the duration and severity of neutropenia, with evidence suggesting a potential increase in infection risk and treatment delays 3

The American Society of Clinical Oncology recommends monitoring blood counts at the start of therapy and prior to each subsequent cycle, and considering dose modification if the platelet count falls below 50,000/mm³ or the absolute neutrophil count falls below 500/mm³, although the exact citation for this is not provided, similar guidelines are supported by 1